Abstract
Objectives
To compare the effects of typical and atypical antipsychotic drugs on sleep activity and subjective sleep quality.
Design
Randomised, double-blind, placebo-controlled, four-period cross-over, clinical trial was used to evaluate the effects of active treatments on objective and subjective sleep variables.
Setting
Sleep laboratory evaluation.
Participants
Twenty healthy young volunteers, both sexes.
Interventions
Single oral morning administrations of olanzapine 5 mg, risperidone 1 mg, haloperidol 3 mg and placebo.
Measurements and results
Five polysomnographic nights were evaluated: one control night and one after each intervention. Significant increase in total sleep time, sleep efficiency, slow wave sleep (SWS) and rapid eye movement (REM) sleep with decreases in wake time were observed after olanzapine. Decreases in wake time, REM sleep and stage shifts together with increases in stage 2 were obtained after risperidone. Haloperidol showed only a tendency to increase sleep efficiency and stage 2 and to decrease wake time. Olanzapine showed decreases in power density in frequencies higher than 10 Hz during all sleep stages and in frequencies lower than 5 Hz range in SWS; decreases in the dynamics of spindle frequency activity (SFA) in the second and fourth non-rapid eye movement (NREM) episodes were also obtained. Risperidone presented increases in the 3.6–10.8 Hz frequency range in NREM sleep stages and in stage 2. Haloperidol also showed increases in NREM sleep stages and in stage 2, but these were in frequencies higher than 10 Hz, with increases in the dynamics of SFA in the first NREM episode. Only a significant improvement in subjective sleep quality was observed after olanzapine.
Conclusions
Antipsychotics showed different sleep changes as their neurochemical profiles were distinct. These changes were observed even when the drug was administered 15 h before going to bed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aeschbach D, Borbély AA (1993) All night dynamics of the human sleep EEG. J Sleep Res 2:70–81
Åkerstedt T, Hume K, Minors D, Waterhouse J (1994a) The meaning of good sleep: a longitudinal study of polysomnography and subjective sleep quality. J Sleep Res 3:152–158
Åkerstedt T, Hume K, Minors D, Waterhouse J (1994b) The subjective meaning of good sleep—an intraindividual approach using the Karolinska Sleep Diary. Percept Mot Skills 79:287–296
Åkerstedt T, Hume K, Minors D, Waterhouse J (1997) Good sleep—its timing and physiological characteristics. J Sleep Res 6:221–229
Barbanoj MJ, Grasa E, Morte A, Romero S, Clos S, Giménez S, Benito Ll, Yritia M, Pérez V, Anderer P (2004) Topographic EEG changes after single oral doses of atypical neuroleptics with different pharmacological profile in healthy young subjects (abstract). 13th meeting of the IPEG (International Pharmaco–EEG Society), Amberes, Belgium (8–12 September)
Borbély AA, Mattmann P, Loepfe M, Strauch I, Lehmann D (1983) Effect of benzodiazepine hypnotics on all-night sleep EEG spectra. Hum Neurobiol 4:189–194
Bobérly AA, Trachsel L, Tobler I (1988) Effect of ritanserin on sleep stages and sleep EEG in the rat. Eur J Pharmacol 156:275–278
Dijk DJ, Beersma DGM, Daan S, Van den Hoofdakker RH (1989) Effects of seganserin, a 5HT2 antagonist, and temazepam on human sleep stages and EEG power spectra. Eur J Pharmacol 171:207–218
Dugovic C, Wauquier A, Janssen PAJ (1989) Differential effects of the new antipsychotic risperidone on sleep and wakefulness in the rat. Neuropharmacology 28:1431–1433
Feinberg I, Floyd TC (1979) Systematic trends across the night in human sleep cycles. Psychophysiology 16:282–291
Itil TM, Gannon P, Hsu W, Klingenberg H (1970) Digital computer analyzed sleep and resting EEG during haloperidol treatment. Am J Psychiatry 127:462–471
Janssen P, Niemeggeers CJ, Awouters F, Schellekens KH, Megens AA, Meert TF (1988) Pharmacology of risperidone (R64766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther 244:685–693
Lee DY, Lee KU, Kwon JS, Jang IJ, Cho MJ, Shin SG, Woo JI (1999) Pharmacokinetic–pharmacodynamic modeling of risperidone effects on electroencephalography in healthy volunteers. Psychopharmacology 144:272–278
Lindberg N, Virkkunen M, Tani P, Appelberg B, Virkkala J, Rimón R, Porkka-Heiskanen T (2002) Effect of a single-dose of olanzapine on sleep in healthy females and males. Int Clin Psychopharmacol 17:177–184
Maixner S, Tandon R, Eiser A, Taylor S, DeQuardo JR, Shipley J (1998) Effects of antipsychotic treatment on polysomnographic measures in schizophrenia: a replication and extension. Am J Psychiatry 155:1600–1602
Miyamoto S, Duncan GE, Goff DC, Lieberman JA (2002) Therapeutics of schizophrenia. In: Davis KL, Charney D, Coyle JT, Nemeroff C (eds) American College of Neuropsychopharmacology: the fifth generation of progress. Lippincott, Williams and Wilkins, Philadelphia, PA, pp 775–807
Nicholson AN, Pascoe PA (1991) Presynaptic alpha 2-adrenoceptor function and sleep in man: studies with clonidine and idazoxan. Neuropharmacology 30:367–372
Pace-Schott EF, Hobson JA (2002) Basic mechanisms of sleep: new evidence on the neuroanatomy and neuromodulation of the NREM–REM cycle. In: Davis KL, Charney D, Coyle JT, Nemeroff C (eds) American College of Neuropsychopharmacology: the fifth generation of progress. Lippincott, Williams and Wilkins, Philadelphia, PA, pp 1859–1877
Rechtschaffen A, Kales A (1968) A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. U.S. Government Printing Office, Washington, DC
Saletu B, Wessely P, Grünberger J, Schultes M (1987a). Erste klinische Erfahrungen mit einem neuen schlafanstossenden Benzodiacepin Cinolazepam mittels eines Selbstbeurteilungsbogens für Schalf—und Aufwachqualität (SSA). Neuropsychiatrie 1:169–176
Saletu B, Anderer P, Kinsperger K, Grünberger J (1987b). Topographic brain mapping of EEG in neuropsychopharmacology—Part II. Clinical applications (pharmaco-EEG imaging). Methods Find Exp Clin Pharmacol 9:385–408
Salin-Pascual RJ, Herrera-Estrella M, Galicia-Polo L, Rosas-Laurrabaquio M (1999) Olanzapine acute administration in schizophrenic patients increases delta sleep and sleep efficiency. Biol Psychiatry 46:141–143
Salin-Pascual RJ, Herrera-Estrella M, Galicia-Polo L, Rosas M, Brunner E (2004) Low delta sleep predicted a good clinical response to olanzapine administration in schizophrenic patients. Rev Invest Clin 56:345–350
Schlösser R, Röschker J, Rossbach W, Benkert O (1998) Conventional and spectral power analysis of all-night sleep EEG after subchronic treatment with paroxetine in healthy male volunteers. Eur Neuropsychopharmacol 8:273–278
Sharpley AL, Elliott JM, Attenburrow MJ, Cowen PJ (1994) Slow wave sleep in humans: Role of 5-HTA and 5HT2C receptors. Neuropharmacology 33:467–471
Sharpley AL, Vassallo CM, Cowen PJ (2000) Olanzapine increases slow-wave sleep: evidence for blockade of central 5-HT2c receptors in vivo. Biol Psychiatry 47:468–470
Sharpley AL, Bhagwagar Z, Hafizi S, Whale WR, Gijsman HJ, Cowen PJ (2003) Risperidone augmentation decreases rapid eye movement sleep and decreases wake in treatment-resistant depressed patients. J Clin Psychiatry 64:192–196
Stephan FT, Tandon R, Shipley JE, Eiser AS (1991) Effect of neuroleptic treatment on polysomnographic measures in schizophrenia. Biol Psychiatry 30:904–912
Tandon R (1998) Antipsychotic agents. In: Klein DF, Rowland LP (eds) Current psychotherapeutic drugs. Brunner/Mazel Publishers, New York, pp 120–154
Viola AU, Brandenberger G, Toussaint M, Bouhours P, Macher JP, Luthringer R (2002) Ritanserin, a serotonin-2 receptor antagonist, improves ultradian sleep rhythmicity in young poor sleepers. Clin Neurophysiol 113:429–434
Warrington SJ (1997) Ethical aspects of research in healthy volunteers. In: O’Grady J, Joubert PH (eds) Handbook of phase I/II clinical drug trials. CRS Press, Boca Raton, pp 103–110
Worrel JA, Marken PA, Beckman SE, Ruether VL (2000) Atypical antipsychotic agents: a critical review. Am J Health—Syst Pharm 57:238–255
Acknowledgment
The authors thank the staff at the Centre d’Investigació de Medicaments de l’Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau, in particular, Liria da Graça for the technical assistance during data collection, and Angeles Funes for typing the manuscript. Supported by a grant from the Fundació La Marató de TV3 (Catalonia Television, Spain).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Giménez, S., Clos, S., Romero, S. et al. Effects of olanzapine, risperidone and haloperidol on sleep after a single oral morning dose in healthy volunteers. Psychopharmacology 190, 507–516 (2007). https://doi.org/10.1007/s00213-006-0633-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-006-0633-7